Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 15 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Q/C TECHNOLOGIES, INC.

QuidelOrtho Corp

Deeply undervalued

Discount 75% Return to IV: +297.5%

Market implies -21.7%/yr vs model +17.1% · below model

Discount 15% Return to IV: +17.2%

Owner yield 4.6% 10-yr IRR 5.8% · steady

Market implies +1.9%/yr vs model +4.5% · in line

Quince Therapeutics, Inc.

Quoin Pharmaceuticals, Ltd.

Quantum Biopharma Ltd.

Market implies +74.6%/yr vs model +15.0% · above model

Market implies +28.1%/yr vs model +15.0% · above model

QTREX Quantum Ltd.

Market implies +77.0%/yr vs model +15.0% · above model

QT IMAGING HOLDINGS, INC.

Deeply undervalued

Discount 32% Return to IV: +46.1%

Market implies -12.6%/yr vs model +15.0% · below model

Deeply overvalued

Premium +89% Return to IV: -47.0%

Market implies +8.9%/yr vs model +5.9% · above model

Premium +17% Return to IV: -14.7%

Market implies -6.3%/yr vs model +12.2% · below model

Quantum Cyber N.V.

Market implies +60.5%/yr vs model +15.0% · above model

Market implies +65.5%/yr vs model +2.0% · above model

Radiopharm Theranostics Ltd

Deeply overvalued

Premium +136% Return to IV: -57.7%

Owner yield 5.3% 10-yr IRR 6.6% · steady

Market implies +15.2%/yr vs model +3.0% · above model

Rani Therapeutics Holdings, Inc.

Rapport Therapeutics, Inc.

Ultragenyx Pharmaceutical Inc.

Deeply overvalued

Premium +45% Return to IV: -31.0%

Market implies +4.8%/yr vs model +17.6% · below model

AVITA Medical, Inc.

Deeply overvalued

Premium +256% Return to IV: -71.9%

Market implies +19.0%/yr vs model +24.8% · below model

ROCKET PHARMACEUTICALS, INC.

ROCKET PHARMACEUTICALS, INC.

Arcus Biosciences, Inc.

Market implies +101.2%/yr vs model +2.0% · above model

RedHill Biopharma Ltd.

Premium +19% Return to IV: -16.1%

Market implies +11.3%/yr vs model +11.1% · in line

DR REDDYS LABORATORIES LTD

REGENERON PHARMACEUTICALS, INC.

Deeply overvalued

Model IV$601.17

Premium +31% Return to IV: -23.4%

Owner yield 4.5% 10-yr IRR 5.1% · steady

Market implies +6.8%/yr vs model +3.8% · in line

Replimune Group, Inc.

REVELATION BIOSCIENCES, INC.

REVELATION BIOSCIENCES, INC.

Rafael Holdings, Inc.

Market implies +118.2%/yr vs model +2.0% · above model

Regencell Bioscience Holdings Ltd

REGENTIS BIOMATERIALS LTD.

Market implies +57.1%/yr vs model +2.0% · above model

RIGEL PHARMACEUTICALS INC

Deeply undervalued

Model IV$117.12

Discount 60% Return to IV: +147.9%

Market implies +2.0%/yr vs model +20.0% · below model

Relay Therapeutics, Inc.

Market implies +64.5%/yr vs model +50.0% · above model

RELMADA THERAPEUTICS, INC.

Market implies +56.9%/yr vs model +15.0% · above model

Deeply undervalued

Model IV$375.92

Discount 40% Return to IV: +67.1%

Owner yield 3.6% 10-yr IRR 7.9% · moderate

Market implies +3.5%/yr vs model +11.9% · below model

ROCKWELL MEDICAL, INC.

Deeply undervalued

Premium +304% Return to IV: -75.2%

Market implies +12.8%/yr vs model +2.8% · above model

Atrium Therapeutics, Inc.

Cartesian Therapeutics, Inc.

Market implies +104.6%/yr vs model +2.0% · above model

Transcode Therapeutics, Inc.

Rein Therapeutics, Inc.

Market implies +48.2%/yr vs model +15.0% · above model

Roivant Sciences Ltd.

Market implies +144.2%/yr vs model +2.0% · above model

ROCKWELL AUTOMATION, INC

Deeply overvalued

Model IV$170.13

Premium +144% Return to IV: -59.1%

Owner yield 2.3% 10-yr IRR -1.0% · moderate

Market implies +18.3%/yr vs model +7.0% · above model

ROPER TECHNOLOGIES INC

Deeply undervalued

Model IV$995.98

Discount 63% Return to IV: +167.2%

Market implies -1.8%/yr vs model +12.2% · below model

RAPID MICRO BIOSYSTEMS, INC.

Market implies +21.1%/yr vs model +9.7% · above model

Royalty Pharma plc

Deeply undervalued

Model IV$108.10

Discount 46% Return to IV: +84.4%

Market implies -4.4%/yr vs model +3.7% · below model

Revolution Medicines, Inc.

Market implies +126.5%/yr vs model +15.0% · above model

Revolution Medicines, Inc.

Market implies +91.9%/yr vs model +2.0% · above model

RETRACTABLE TECHNOLOGIES INC

Deeply undervalued

Discount 46% Return to IV: +85.3%

Market implies -18.8%/yr vs model +2.0% · below model

Deeply overvalued

Premium +233% Return to IV: -70.0%

Owner yield 2.1% 10-yr IRR -5.3% · steady

Market implies +19.0%/yr vs model +2.0% · above model

RECURSION PHARMACEUTICALS, INC.

Market implies +35.4%/yr vs model +50.0% · below model

Deeply undervalued

Discount 60% Return to IV: +152.6%

Market implies -15.6%/yr vs model +50.0% · below model

RHYTHM PHARMACEUTICALS, INC.

Deeply overvalued

Premium +406% Return to IV: -80.2%

Market implies +21.8%/yr vs model +50.0% · below model

SAB Biotherapeutics, Inc.

Market implies +60.4%/yr vs model +15.0% · above model